Mauricio serves as Editor in PharmaBoardroom since 2020, previously he has been involved in editorial project management within the organisation and has multiple years of experience as news reporter and contributor.
There are perhaps no two words that better summarize the last few years in Turkish pharma than localization and pricing. But after years of investment and struggles, the country’s priorities…
As the Saudi pharma market – worth approximately USD 8.2 billion – continues to grow, so does the need for pharma companies to efficiently distribute their medicines inside the Kingdom.…
After 20 years, Novartis will no longer own one third of Roche’s shares after the two Swiss pharma giants agreed to a transaction worth USD 20.7 billion. While Roche touted…
While supporters of Turkey’s localization policy for pharmaceuticals implemented in 2016 applaud the changes it has brought, its opponents are awaiting a much-anticipated report by the World Trade Organization that…
After a challenging 2020, and with more hurdles in sight, Bayer has been on an investment spree with a USD 2 billion acquisition of a San Diego-based biotech and manufacturing…
The latest from the healthcare industry in Latin America, including an alarming OECD report about the decline of well-being in the region due to Covid-19, Bayer’s USD 350 million investment…
Three months after the World Bank announced a EUR 600 million loan to South Africa’s Aspen Pharmacare, the African continent has received more good news as it seeks to increase…
In the world’s 18th largest market, recent pricing struggles have pushed some companies to revaluate their investment approach. Multinational organizations are complying with localization policies but are divided between having…
Boehringer Ingelheim (BI), the largest private pharma company in the world, has become the latest Big Pharma player to commit to Turkish localization after announcing a contract manufacturing partnership with…
A roundup of the latest news from South African pharma, including Aspen’s impressive annual growth, Adcock Ingram’s full year profit drop, and Entos Pharma’s approval for Phase II clinical rials…
Looking to diversify its economy while simultaneously improving its healthcare system, Saudi Arabia has been rolling out incentives for international companies to invest in local manufacturing. Here are three trends…
Drawing on over a dozen interviews with C-level pharmaceutical industry executives in Turkey, PharmaBoardroom has compiled a strategic overview of Turkey’s pharma talent potential, including what local talent can offer…
See our Cookie Privacy Policy Here
